

Systemic treatment for advanced hepatocellular carcinoma

- Live streaming from the UK with Prof. Jeff Evans

MSD and Eisai are pleased to invite you for a live webcast with a renowned scientific leader in the field of hepatocellular carcinoma, Prof. Jeff Evans.

Date: Tuesday, 03 November 2020

Time: 12:00 - 13.00 (Swedish time)



Webcast agenda

Time	Topic	Speaker
12.00 (UTC +2)	Welcome & Introduction	Stéphanie Caruccio Björknesjö (Oncology Therapy Area Manager MSD)
12.05 (UTC+2)	<ul style="list-style-type: none">• Introduction to hepatocellular carcinoma (HCC)• Systemic treatment for advanced HCC• Clinical practice knowledge exchange	Prof. Jeff Evans Clinical Director, Institute of Cancer Sciences, Glasgow University
12.45 (UTC+2)	Q&A session	Stéphanie Caruccio Björknesjö (Oncology Therapy Area Manager MSD Sweden) Jakob Regberg (Medical Science Liaison Oncology - Eisai Nordics)

Attendance to this event is possible in two ways:



1. At your office/home, via the webcast link
<https://webinars.on24.com/msdsweden/hepatocellularCarcinoma?Partnerref=OtolookApprovedEmail>
2. Together with your colleagues if your hospital is having a streaming site. Please still register via the link so we can order lunch for you. If you're interested in having a streaming site at your hospital please contact andrea.brannstrom@eisai.net and/or stephanie.bjorknesjo@merck.com



About the speaker

Prof. Jeff Evans is the Director of the Institute of Cancer Sciences at the University of Glasgow and a Professor of Translational Cancer Research. He is also the Lead of the Glasgow Experimental Cancer Medicine Centre and the Head of the Experimental Cancer Therapeutics Unit.



Prof. Evans holds the title as Honorary Group Leader at the CRUK Beatson Institute. Furthermore, he is the co-editor of the clinical research section of the British Journal of Cancer and has been an experienced investigator in key studies involving hepatocellular carcinoma.

His clinical research interests are in the pre-clinical and clinical development of novel anti-cancer agents including molecular targeted therapies and gene therapy. Prof. Evans run a number of Phase 1 clinical trials of innovative anti-cancer agents, and also runs the Analytical Services Unit at the Centre for Oncology and Applied Pharmacology, University of Glasgow. His clinical research interests also include the development of novel therapies for gastro-esophageal and hepato-biliary-pancreatic cancers and melanoma.

Please note:

- By completing this registration I give my consent for MSD to process the personal information provided in this form for the purposes organizing the meeting. I agree to the terms and conditions related to the processing of my personal information as explained below.
- We will use the personal information provided by you for the purpose of arranging the meeting. The information provided will be stored for 5 years, in a location accessible only by MSD personnel who require access to this data in order to fulfill their duties. This use of your personal data is based on your consent as indicated in this form and our legitimate interest in providing our services to you. Your personal information is stored and processed in accordance with the GDPR. You have the right to request access, rectification, and erasure of your personal information. You also have the right to restrict processing, the right to data portability, as well as the right to object and rights related to automated individual decision making.

Please direct all your queries related to these rights to dpo.sweden@merck.com

*MSD and Eisai covers the cost of the lunch at the dedicated streaming sites
in the presence of a MSD or an Eisai representative*

